# Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC

> **NCT05167604** · — · UNKNOWN · sponsor: **Tang-Du Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Next-Generation Sequencing
- Chemotherapy, Adjuvant
- Neoplasm, Residual
- Circulating Tumor DNA

## Interventions

- **DRUG:** Adjuvants, Pharmaceutic

## Key facts

- **NCT ID:** NCT05167604
- **Lead sponsor:** Tang-Du Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-30
- **Primary completion:** 2023-09
- **Final completion:** 2024-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2021-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05167604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05167604, "Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05167604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*